<DOC>
	<DOCNO>NCT00330460</DOCNO>
	<brief_summary>The purpose study determine whether postmenopausal woman low bone mineral density , mean percent change total hip BMD subject receive denosumab less observed subject receive alendronate sodium pre-specified non-inferiority margin .</brief_summary>
	<brief_title>A Randomized , Double-Blind Study Compare Efficacy Treatment With Denosumab Versus Alendronate Sodium Postmenopausal Women With Low Bone Mineral Density .</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>Patient ambulatory postmenopausal woman Patient BMD value correspond Tscore less equal 2.0 ( g/cm2 ) lumbar spine OR total hip within range specific study protocol . Any disorder compromise ability subject give write informed consent and/or comply study procedure Evidence follow per subject report , chart review central laboratory result : 1 . Hyper hypothyroidism ; however , subject stable thyroid hormone replacement therapy may allow per follow criterion : If TSH level normal , subject eligible study . If TSH level normal range , subject eligible study . If TSH level elevate ( &gt; 5.5 mIU/mL 10.0 mIU/mL ) , serum T4 measure . If serum T4 within normal range , subject eligible . If serum T4 outside normal range , subject eligible study . If TSH level 10.0 mIU/mL , subject eligible . 2 . Current hyper hypoparathyroidism 3 . Elevated transaminase Serum aspartate aminotransferase ( AST ; serum glutamateoxaloacetic transaminase [ SGOT ] ) ³ 2.0 x upper limit normal ( ULN ) Serum alanine aminotransferase ( ALT ; serum glutamatepyruvate transaminase [ SGPT ] ) ³ 2.0 x ULN 4 . Significantly impaired renal function determine serum creatinine ³ 2.0 mg/dL 5 . Current hypo hypercalcemia base central laboratory reference range 6 . Active gastric duodenal ulcer ; history significant gastrointestinal bleed require hospitalization transfusion , dyspepsia gastroesophageal reflux disease uncontrolled medication 7 . Rheumatoid Arthritis , Paget 's disease , Cushing 's disease , hyperprolactinemia , cirrhosis liver 8 . Known test positive human immunodeficiency virus , hepatitis C virus , hepatitis B surface antigen 9 . Malignancy ( except fully resect cutaneous basal cell squamous cell carcinoma , cervical breast ductal carcinoma situ ) within last 5 year 10 . Any metabolic bone disease , eg , osteomalacia osteogenesis imperfecta , may interfere interpretation finding 11 . Malabsorption syndrome gastrointestinal disorder associate malabsorption Received solid organ bone marrow transplant Vitamin D deficiency ( 25 ( OH ) vitamin D level &lt; 12 ng/mL ) . Vitamin D repletion permit subject may rescreened ; see Section 7 . Any laboratory abnormality , opinion investigator , prevent subject complete study interfere interpretation study result Contraindicated poorly tolerant ALN therapy ; contraindication ALN therapy include : 1 . Abnormalities esophagus , delay esophageal emptying stricture achalasia . 2 . Inability stand sit upright least 30 minute . 3 . Hypersensitivity ALN constituent ALN tablet Known sensitivity mammalian cell derive drug product Known intolerance calcium supplement Administration intravenous bisphosphonate , fluoride ( except dental treatment ) strontium ranelate Oral bisphosphonate treatment : ³ 3 month cumulatively past 2 year , OR ³ 1 month past year , OR Any use 3month period prior randomization PTH PTH derivative ( eg , teriparatide ) within last year Administration follow treatment within 3 month randomization : 1 . Any SERM ( eg , raloxifene ) 2 . Tibolone 3 . Anabolic steroid testosterone 4 . Glucocorticosteroids ( ³ 5 mg prednisone equivalent per day 10 day ) 5 . Systemic ( oral , transdermal , topical ) hormone replacement therapy ( local vaginal estrogen preparation allow ) 6 . Calcitonin 7 . Calcitriol vitamin D derivatives 8 . Other bone active drug include anticonvulsives ( except benzodiazepine ) heparin 9 . Chronic systemic ketoconazole , androgen , ACTH , cinacalcet , aluminum , lithium , protease inhibitor , methotrexate , gonadotropinreleasing hormone agonists 10 . Height , weight girth may preclude accurate DXA measurement Less 2 lumbar vertebra ( L1L4 ) evaluable DXA measurement Both hip evaluable DXA ( eg , history bilateral hip replacement pin hip ) Currently enrol yet complete least 1 month since end investigational device drug trial ( ) , subject receive investigational agent ( ) Any physical psychiatric disorder , opinion investigator , prevent subject complete study interfere interpretation study result Evidence alcohol substanceabuse within last 12 month investigator believe would interfere understand complete study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>Osteopenia</keyword>
	<keyword>AMG 162</keyword>
	<keyword>Fracture - hip</keyword>
	<keyword>Postmenopausal</keyword>
</DOC>